热门资讯> 正文
BRIEF-Onvansertib Trial In KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across Kras Mutation Subtype
2020-04-28 20:19
April 28 (Reuters) - Trovagene Inc :
* ONVANSERTIB TRIAL IN KRAS-MUTATED COLORECTAL CANCER DEMONSTRATES CONSISTENT TUMOR REGRESSION ACROSS KRAS MUTATION SUBTYPES AND DURABLE RESPONSE
* TROVAGENE INC - IN PHASE 1B DOSE ESCALATION, 1ST TWO DOSE LEVELS (ONVANSERTIB 12 MG/M(2 )AND 15 MG/M(2)) HAVE BEEN CLEARED FOR SAFETY
* TROVAGENE INC - 3RD DOSE LEVEL (ONVANSERTIB 18 MG/M(2)) IS ENROLLING; MAXIMUM TOLERATED DOSE HAS NOT BEEN REACHED TO-DATE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
